Lupin is currently trading at Rs. 930.25, up by 5.20 points or 0.56% from its previous closing of Rs. 925.05 on the BSE.
The scrip opened at Rs. 925.50 and has touched a high and low of Rs. 933.80 and Rs. 925.50 respectively. So far 67021 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.
Last one week high and low of the scrip stood at Rs. 933.80 and Rs. 870.10 respectively. The current market cap of the company is Rs. 42038.56 crore.
The promoters holding in the company stood at 47.02%, while institutions and non-institutions held 37.64% and 15.35% respectively.
Lupin is reportedly targeting for $54 billion complex generics market as it tries to insulate itself from increasing competition and consolidation of distribution channel in US in plain vanilla copycat drugs. Of $98 billion products under development, 55% will come from complex categories like biosimilars, inhalation, depot injectables, opthalmic and topical dermatological drugs.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
